Shield Receives College of American Pathology (CAP) Accreditation

SAN JOSE, Calif., August 13, 2019 - Shield, an Andreessen Horowitz-backed biotechnology company tackling antibiotic resistance by bringing precision medicine to infectious disease, announced today that it has been awarded accreditation by the College of American Pathologists (CAP).

“Receiving CAP accreditation is an important recognition of our laboratory. It means that our test results are meeting and exceeding industry standards for clinical laboratory testing.” said Arthur Baca, M.D. Ph.D., Laboratory Director.

Shield’ Chief Executive Officer, Fred Turner, upon learning of the laboratory’s accreditation, said: “We are proud of our diligent and experienced clinical lab team. Their meticulous work ensures that we maintain the highest standards of excellence in laboratory practices. By providing accurate and rapid test results for the susceptibility of pathogens to less potent antibiotics, we hope to end the abuse of our last defense antibiotics.”

During the CAP accreditation process, inspectors perform an on-site inspection and examine the laboratory’s records and quality control of procedures for the preceding two years. CAP inspectors also examine laboratory staff qualifications, equipment, facilities, safety program and record, and overall management.

About the College of American Pathologists

As the world’s largest organization of board-certified pathologists and leading provider of laboratory accreditation and proficiency testing programs, the College of American Pathologists (CAP) serves patients, pathologists, and the public by fostering and advocating excellence in the practice of pathology and laboratory medicine worldwide. For more information, read the CAP Annual Report at cap.org.

About Shield

Shield is a biotechnology company with a vision of preventing antibiotic resistance from growing deadlier than cancer. With a mission to enable resistance-guided therapy, Shield is developing rapid molecular testing to target antibiotic use to the specific infection. Our first rapid molecular test, Target-NG, evaluates gonorrhea infections for antibiotic susceptibility to ciprofloxacin, as a reflex to gonorrhea, chlamydia, and trichomoniasis testing in our CLIA & CAP accredited laboratory in San Jose, CA. Currently, Shield is the only laboratory in the industry that offers a gonorrhea reflex test for antibiotic susceptibility to ciprofloxacin. For more information, visit https://shieldbio.com/.

Media Contact:

Margaret Theeuwes
press@shieldbio.com

Investor Contact:

Fred Turner, CEO
investors@shieldbio.com